Trends in reperfusion therapy of ST segment elevation myocardial infarction in Switzerland: six year results from a nationwide registry by Fassa, A A et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2005
Trends in reperfusion therapy of ST segment elevation
myocardial infarction in Switzerland: six year results from a
nationwide registry
Fassa, A A; Urban, P; Radovanovic, D; Duvoisin, N; Gaspoz, J M; Stauffer, J C; Erne,
P
Fassa, A A; Urban, P; Radovanovic, D; Duvoisin, N; Gaspoz, J M; Stauffer, J C; Erne, P (2005). Trends in
reperfusion therapy of ST segment elevation myocardial infarction in Switzerland: six year results from a
nationwide registry. Heart (British Cardiac Society), 91(7):882-888.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Heart (British Cardiac Society) 2005, 91(7):882-888.
Fassa, A A; Urban, P; Radovanovic, D; Duvoisin, N; Gaspoz, J M; Stauffer, J C; Erne, P (2005). Trends in
reperfusion therapy of ST segment elevation myocardial infarction in Switzerland: six year results from a
nationwide registry. Heart (British Cardiac Society), 91(7):882-888.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Heart (British Cardiac Society) 2005, 91(7):882-888.
Trends in reperfusion therapy of ST segment elevation
myocardial infarction in Switzerland: six year results from a
nationwide registry
Abstract
OBJECTIVE: To document the trends in reperfusion therapy for ST segment elevation myocardial
infarction (STEMI) in Switzerland. DESIGN: National prospective multicentre registry, AMIS Plus
(acute myocardial infarction and unstable angina in Switzerland), of patients admitted with acute
coronary syndromes. SETTING: 54 hospitals of varying size and capability in Switzerland. PATIENTS:
7098 of 11 845 AMIS Plus patients who presented with ST segment elevation or left bundle branch
block on the ECG at admission. MAIN OUTCOME MEASURES: In-hospital mortality and its
predictors at admission by multivariate analysis. RESULTS: The proportion of patients treated by
primary percutaneous coronary intervention (PCI) progressively increased from 1997 to 2002, while the
proportion with thrombolysis or no reperfusion decreased (from 8.0% to 43.1%, from 47.2% to 25.6%,
and from 44.8% to 31.4%, respectively). Overall in-hospital mortality decreased over the study period
from 12.2% to 6.7% (p < 0.001). Main in-hospital mortality predictors by multivariate analysis were
primary PCI (odds ratio (OR) 0.52, 95% confidence interval (CI) 0.33 to 0.81), thrombolysis (OR 0.63,
95% CI 0.47 to 0.83), and Killip class III (OR 3.61, 95% CI 2.49 to 5.24) and class IV (OR 5.97, 95%
CI 3.51 to 10.17) at admission. When adjusted for the year, multivariate analysis did not show PCI to be
significantly superior to thrombolysis for in-hospital mortality (OR 1.2 for PCI better, 95% CI 0.8 to
1.9, p = 0.42). CONCLUSION: Primary PCI has become the preferred mode of reperfusion for STEMI
since 2002 in Switzerland, whereas use of intravenous thrombolysis has decreased from 1997 to 2002.
Furthermore, there was a major reduction of in-hospital mortality over the same period.
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Objective: To document the trends in reperfusion therapy for ST segment elevation myocardial infarction
(STEMI) in Switzerland.
Design: National prospective multicentre registry, AMIS Plus (acute myocardial infarction and unstable
angina in Switzerland), of patients admitted with acute coronary syndromes.
Setting: 54 hospitals of varying size and capability in Switzerland.
Patients: 7098 of 11 845 AMIS Plus patients who presented with ST segment elevation or left bundle
branch block on the ECG at admission.
Main outcome measures: In-hospital mortality and its predictors at admission by multivariate analysis.
Results: The proportion of patients treated by primary percutaneous coronary intervention (PCI)
progressively increased from 1997 to 2002, while the proportion with thrombolysis or no reperfusion
decreased (from 8.0% to 43.1%, from 47.2% to 25.6%, and from 44.8% to 31.4%, respectively). Overall
in-hospital mortality decreased over the study period from 12.2% to 6.7% (p , 0.001). Main in-hospital
mortality predictors by multivariate analysis were primary PCI (odds ratio (OR) 0.52, 95% confidence
interval (CI) 0.33 to 0.81), thrombolysis (OR 0.63, 95% CI 0.47 to 0.83), and Killip class III (OR 3.61, 95%
CI 2.49 to 5.24) and class IV (OR 5.97, 95% CI 3.51 to 10.17) at admission. When adjusted for the year,
multivariate analysis did not show PCI to be significantly superior to thrombolysis for in-hospital mortality
(OR 1.2 for PCI better, 95% CI 0.8 to 1.9, p = 0.42).
Conclusion: Primary PCI has become the preferred mode of reperfusion for STEMI since 2002 in
Switzerland, whereas use of intravenous thrombolysis has decreased from 1997 to 2002. Furthermore,
there was a major reduction of in-hospital mortality over the same period.
S
ince it was found in the mid 1970s that acute myocardial
infarction resulted from a ruptured atherosclerotic
plaque, causing thrombosis and occlusion of a coronary
artery,1 and that restoration of flow salvages myocardium,
major attention has been focused on reperfusion therapy.
Several studies have documented the survival benefit
provided by a thrombolytic, first by intracoronary adminis-
tration and later intravenously.2–5 Numerous randomised
controlled trials soon followed comparing intravenous
thrombolysis with mechanical reperfusion by primary percu-
taneous coronary intervention (PCI). A meta-analysis of 23
randomised controlled trials comparing these two modes of
reperfusion in ST segment elevation myocardial infarction
(STEMI) showed a greater benefit associated with primary
PCI in terms of short and long term mortality, non-fatal
reinfarction, and stroke.6
On the basis of this information, national and international
societies of cardiology have established guidelines concerning
the management of STEMI.7 8 To assess how these translate
into the ‘‘real world’’ of daily clinical practice, several short
and long term registry based studies have been conducted.9–15
Since January 1997, a national prospective registry of
hospital admissions for acute coronary syndromes called
AMIS Plus (acute myocardial infarction and unstable angina
in Switzerland) has been ongoing in Switzerland, with 54 of
the 106 hospitals treating STEMI in Switzerland now
enrolling patients. We used the opportunity offered by this
registry to analyse the current management of acute
myocardial infarction in Switzerland, as well as trends over
time, as a way to assess the impact of guidelines and major
randomised controlled trials on everyday practice in
Switzerland.
METHODS
The AMIS Plus project is a nationwide prospective registry of
patients admitted with acute coronary syndromes to hospi-
tals in Switzerland. The registry began in 1997 and has since
then been recruiting patients. At the time of the present
analysis, 54 of the 106 hospitals treating STEMI in
Switzerland, ranging from community institutions to large
tertiary facilities, were enrolling patients. Participating
centres provide blinded data for each patient through a
standardised internet or paper based questionnaire. The data
are centralised at the Institute of Social and Preventive
Medicine at the University of Zurich, where the data are
checked for plausibility and consistency and incomplete
questionnaires are returned to the enrolment centres for
completion. The registry was approved by the Above-Regional
Ethics Committee for Clinical Studies and the Swiss Board
for Data Security. The AMIS Plus project is officially
supported by the Swiss societies of cardiology, internal
medicine, and intensive care medicine and is sponsored by
Abbreviations: AMIS Plus, acute myocardial infarction and unstable
angina in Switzerland; CK, creatine kinase; MIR, myocardial infarction
registry; MITRA, maximal individual therapy in acute myocardial
infarction; NRMI 3, national registry of myocardial infarction 3; PCI,
percutaneous coronary intervention; STEMI, ST segment elevation
myocardial infarction
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unrestricted grants from the Swiss Heart Foundation as well
as a number of pharmaceutical and medical device compa-
nies (listed in the acknowledgements).
The questionnaire comprises 140 items for each patient and
is filled in by the coordinator of each institution. It seeks
information regarding medical history and existing co-
morbidities, known cardiovascular risk factors, acute symp-
toms, out of hospital management, clinical presentation,
early (first 48 hours) in-hospital management, reperfusion
therapy, hospital course, diagnostic tests used or planned,
hospital length of stay, and discharge medication and
destination.
Patients are enrolled in the registry on the basis of their
final diagnosis, which must comply with one of the three
following definitions: acute myocardial infarction (symptoms
or ECG changes compatible with acute coronary syndrome, or
both, and cardiac enzymes (total creatine kinase (CK) or CK-
MB) at least twice the upper limit of normal range); acute
coronary syndrome with minimum necrosis (symptoms or
ECG changes compatible with acute coronary syndrome, or
both, and cardiac enzymes (total CK or CK-MB) lower than
twice the upper limit of normal range, and positive
troponins); and unstable angina (symptoms or ECG changes
compatible with acute coronary syndrome, or both, and
normal cardiac enzymes). Cases that are of unclear or non-
cardiac cause are not included.
Patient selection
The present analysis was based on patients satisfying the
criteria for one of the three categories stated above and who
were admitted with a suspected STEMI as an initial
diagnosis. Therefore, we selected the patients from the 54
participating centres between January 1997 and December
2002 in the AMIS Plus registry who presented with ST
segment elevation or a left bundle branch block on the
admission ECG.
Statistical analysis
Data concerning patients were analysed according to the
mode of reperfusion received: primary PCI, thrombolysis, and
no reperfusion. Discrete variables are presented as absolute
numbers and percentages and continuous variables are
presented as mean (SD) or median. Group differences
were compared by the non-parametric Pearson x2 test
for discrete data and by analysis of variance for continuous
data. A probability value of p , 0.05 was considered
significant.
A multivariate logistic regression model (backwards
logistic regression method) was used to determine in-
hospital mortality predictors from the following set of
variables: admission year; age; sex; systolic and diastolic
blood pressures; heart rate; history of arterial hypertension;
history of hyperlipidaemia; history of diabetes; current
smoking status; cardiopulmonary resuscitation before admis-
sion; defibrillation/cardioversion before admission; Killip
class at hospital admission (class I as reference category);
delay between symptom onset and admission to hospital . 6
hours; Q waves on initial ECG; left bundle branch block on
initial ECG; ST segment elevation on initial ECG; thrombo-
lysis (‘‘no reperfusion’’ as reference category); and primary
PCI (‘‘no reperfusion’’ as reference category). Separate
univariate logistical models were first fitted for each
variable and then backwards elimination with a signi-
ficance level of 0.05 was performed. Odds ratios were
simultaneously adjusted for all the other predictors
included in the multivariate logistic regression model.
An additional logistic regression model was adjusted for
the admission year to analyse whether the difference in
in-hospital mortality between thrombolysis and PCI
was an artefact in relation to the changes in reperfusion
therapy.
SPSS (version 11.5, SPSS Inc, Chicago, Illinois, USA) was
used for all statistical analyses.
Table 1 Baseline characteristics of the study population (n = 7098) according to mode of
reperfusion
Patients*
Primary PCI
n = 1419
Thrombolysis
n = 2833
No reperfusion
n = 2846
Age (years) 7035 (99.1%) 60.2 (12.5) 62.7 (12.4) 70.5 (12.9)
Women 6997 (98.6%) 292 (21.4%) 650 (23.3%) 962 (33.9%)
History of CAD 5106 (71.9%) 372 (30.0%) 516 (28.6%) 933 (45.3%)
Diabetes 6890 (97.1%) 230 (16.7%) 428 (15.6%) 708 (25.6%)
Hypertension 6834 (96.3%) 658 (48.1%) 1231 (45.0%) 1532 (56.1%)
Current smoker 6716 (94.6%) 681 (51.7%) 1297 (47.6%) 865 (32.3%)
Hyperlipidaemia 6476 (93.3%) 827 (62.2%) 1446 (55.3%) 1208 (47.7%)
Haemodynamic parameters at admission
Heart rate (beats/min) 7046 (99.3%) 77.1 (19.5) 76.8 (19.5) 84.4 (24.7)
Systolic BP (mm Hg) 7056 (99.4%) 131.1 (27.3) 136.0 (26.8) 135.4 (29.4)
Diastolic BP (mm Hg) 7034 (99.1%) 77.6 (17.3) 80.5 (18.0) 78.6 (18.8)
Killip class at admission 6903 (97.3%)
I 1119 (80.3%) 2138 (77.7%) 1684 (61.1%)
II 181 (13.0)% 491 (17.8%) 699 (25.4%)
III 38 (2.7%) 79 (2.9%) 285 (10.3%)
IV 56 (4.0%) 44 (1.6%) 89 (3.2%)
Median DSA (hours:minutes) 6406 (90.3%) 3:35 2:33 8:30
ECG at admission
ST elevation 7081 (99.8%) 1373 (96.8%) 2802 (99.0%) 2453 (86.6%)
LBBB 7046 (99.3%) 63 (4.5%) 109 (3.9%) 536 (18.9%)
Q wave 7033 (99.1%) 374 (26.4%) 904 (32.2%) 1150 (41.0%)
Out of hospital management
CPR 6907 (97.3%) 89 (6.4%) 113 (4.1%) 191 (6.9%)
DC shock 6716 (94.6%) 81 (6.5%) 97 (3.6%) 110 (4.0%)
Values are number (%) or mean (SD).
*Patients for whom data were available; p,0.001 across all three groups.
BP, blood pressure; CAD, coronary artery disease, including myocardial infarction, stable angina, ischaemia,
angioplasty, and coronary artery bypass; CPR, cardiopulmonary resuscitation; DC, defibrillation/cardioversion;
DSA, delay between symptom onset and admission to hospital; LBBB, left bundle branch block; PCI, percutaneous
coronary intervention.
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RESULTS
Between January 1997 and December 2002, the 54 partici-
pating centres enrolled 11 845 patients admitted with an
acute coronary syndrome in the AMIS Plus registry. Of these,
7279 patients presented with ST segment elevation or a left
bundle branch block on the admission ECG. Data concerning
reperfusion therapy were unclear or missing for 181 patients,
who were therefore excluded. Thus, the present analysis was
based on 7098 patients.
Table 1 shows patient demographics and characteristics on
hospital admission according to the mode of reperfusion.
These characteristics were similar in the patients who
underwent primary PCI and thrombolysis in terms of age,
sex, cardiovascular risk factors, and haemodynamic and ECG
parameters. However, the patients who did not undergo
reperfusion were older and had a higher rate of diabetes,
hypertension, history of coronary artery disease, and haemo-
dynamic instability at admission; more of them were women,
they more often had a left bundle branch block on their
admission ECG, and more important they had a longer delay
from symptom onset to hospital admission. The question-
naire included an item on the reason why the patients did not
undergo thrombolysis. When excluding the cases where PCI
was preferred instead of thrombolysis (these patients were
included in the primary PCI group), the information was
available for 2224 (78.1%) patients who did not receive any
reperfusion. The main reasons were that these patients were
admitted with too long a delay from their symptom onset
(52.1%), they did not have a certain diagnosis of STEMI, and
they did not have the necessary ECG criteria (28.7%). The
remainder (19.2%) either had a contraindication to throm-
bolysis or declined it.
Analysis of the proportion of patients treated with each
mode of reperfusion from 1997 to 2002 (fig 1) shows the
progressive increase in the use of primary PCI as a mode of
reperfusion throughout the study period (p , 0.001 for
trend). The proportion of patients who received thrombolysis
and those who did not undergo any reperfusion gradually
decreased over the same period (p , 0.001 for both trends).
The proportion of patients undergoing each reperfusion mode
and the calendar year in AMIS Plus and other registries (fig 2)
shows that AMIS Plus is the first registry in which primary
PCI has become the preferred mode of reperfusion for STEMI.
The overall in-hospital mortality for all patients throughout
the study period was 10.1%. The mortality of the patients
who underwent primary PCI, thrombolysis, and no reperfu-
sion was 4.1%, 5.7%, and 17.4%, respectively (p , 0.001).
Furthermore, overall in-hospital mortality decreased signifi-
cantly (p , 0.001) over the study period (fig 3). In-hospital
mortality stratified according to the mode of reperfusion also
decreased significantly in the patients who were treated with
primary PCI (p = 0.032) and in those who did not undergo
reperfusion therapy (p = 0.038) from 1997 to 2002, whereas
mortality did not evolve significantly in the patients treated
with thrombolysis (p = 0.095).
Table 2 gives results of multivariate analysis of predictors
for in-hospital mortality with their odds ratios and 95%
confidence intervals based on 4993 patients (70.3%). Of all
variables included in the model, Killip classes III and IV, pre-
hospitalisation cardiopulmonary resuscitation, and withhold-
ing both primary PCI and thrombolysis were the strongest
predictors of in-hospital mortality. Furthermore, a regression
model comparing in-hospital mortality between reperfusion
therapies, adjusted for the admission year, did not show that
PCI was significantly more beneficial than thrombolysis
(odds ratio 1.2 for a lower mortality associated with PCI; 95%
confidence interval 0.76 to 1.90, p = 0.42).
DISCUSSION
By including a significant number of the hospitals in
Switzerland, the AMIS Plus registry gives an accurate picture
of the contemporary management of acute coronary syn-
dromes in this country. This ongoing multicentre project,
which offers the possibility of both data input and data
analysis over the internet, is a useful tool to monitor current
practices and to assess the impact of major randomised
controlled trials and guidelines.16 17 The present analysis
focused on the immediate reperfusion therapy of STEMI and
its evolution over time.
The patients who underwent reperfusion, either by primary
PCI or by thrombolysis, had a very similar profile. One
notable difference was the delay between the onset of the
symptoms and admission to hospital, which was about one
hour longer for the patients who underwent primary PCI.
Similar findings were described in the MIR (myocardial
infarction registry) and MITRA (maximal individual therapy
No reperfusion (p < 0.001)
Thrombolysis (p < 0.001)
Primary PCI (p < 0.001)
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in acute myocardial infarction) registries9 and may be due to
awareness that the beneficial effect of thrombolysis decreases
with increasing pre-hospital delay.18 This effect does not
apply to the same extent for primary PCI,19–21 therefore
probably leading to a more liberal use of primary PCI for
patients admitted late from the time of symptom onset.
The baseline characteristics were similar to the results of a
previous study by Danchin and colleagues,10 which found no
significant differences between the patients who underwent
primary PCI and thrombolysis in terms of age, sex, and
cardiovascular risk factors. The same study also showed that
patients who did not undergo reperfusion were older and
were admitted to hospital later. In our study, many of the
differences in baseline characteristics between these patients
and those who did undergo PCI or thrombolysis account for
why those patients were not treated. Indeed, late arrival in
hospital after symptom onset was noted to be the reason why
about one half of these patients did not undergo reperfusion.
Another reason stated was the unfulfilled ECG criteria,
probably in relation to the higher rate of left bundle branch
block and lower rate of ST segment elevation present on the
initial ECG in these patients. In addition, the uncertainty of
the diagnosis was also stated as a reason leading to absence
of reperfusion. This may be linked, to a certain extent, to the
higher proportion of women among these patients, who are
known to have a higher incidence of atypical symptoms or
silent myocardial infarctions than men,22–24 thus creating
confusion regarding the establishment of a clear diagnosis.
The higher age and therefore the higher rate of co-
morbidities among these patients may also have influenced
the choice of not performing reperfusion. The integration of
Charlson’s index of co-morbidities in the questionnaire since
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2002,25 which was not used in the present analysis, should
help us in the future to clarify further why any given patient
is selected not to receive reperfusion. Furthermore, the
proportion of patients who did not receive reperfusion
significantly decreased from 1997 to 2002 (from 44.8% to
31.4%). These results are comparable with those reported in
registries that were conducted over the same period (28.8% to
44.2%).11–14 Improvement of referral networks, as well as
continuing efforts to decrease pre-hospital delays, should
help to further reduce the proportion of these patients.
From 1997 to 2002, there was a major increase in the
proportion of patients treated by primary PCI and therefore
this procedure became the preferred mode of reperfusion for
STEMI in 2002. Over the same period, the use of thrombolysis
has gradually decreased. Although this trend has also been
observed in other studies,11 12 the AMIS Plus registry is, to our
knowledge, the first to show that primary PCI has become
the most frequently used means of reperfusion,11–14 certainly
reflecting the impact of the results of several randomised
controlled trials and guidelines for the management of
STEMI,6–8 and showing that recent information is indeed
being translated into clinical practice.
In AMIS Plus, the global in-hospital mortality for STEMI,
regardless of whether reperfusion was carried out, was 10.1%
during the six years of the study, which is comparable with
that reported from NRMI 3 (national registry of myocardial
infarction 3) (9.8% in 1999),10 but slightly higher than the
results reported from other European and international
multicentre studies (6.0–8.0%).12–14 This is probably explained
by the fact that these studies either included a high
proportion of academic medical centres with revascularisa-
tion facilities or had more selective inclusion criteria than in
AMIS Plus (for example, excluding patients who died early in
the emergency room, before admission to the coronary care
unit). Moreover, our study shows a gradual decline of overall
in-hospital mortality for STEMI, from 12.2% in 1997 to 6.7%
in 2002 (p , 0.001). The evolution of in-hospital mortality
stratified according to the reperfusion mode suggests that the
decline of overall mortality during the study period was due
to the simultaneous reduction of the mortality of patients
who underwent PCI, as well as those who did not receive
reperfusion, whereas there was no significant change in the
mortality of the patients who underwent thrombolysis.
The overall in-hospital mortality during the study period
associated with primary PCI and thrombolysis (4.1% and
5.7%, respectively) was similar to the results of previous
registries and randomised trials.6 10 15 A regression model
comparing mortality between both reperfusion modes,
adjusted for the admission year, did not show that primary
PCI was significantly more beneficial than thrombolysis.
However, the mortality associated with primary PCI sig-
nificantly decreased over the study period, whereas the
mortality associated with thrombolysis did not. This dis-
cordance has already been reported previously9 and is
probably due to the fact that thrombolysis has not seen
major advances over the past 10 years, whereas PCI has
progressed greatly over the same period with the improve-
ment of angioplasty technique, broader use of stents and
glycoprotein IIb/IIIa inhibitors, growing experience of the
treating physicians, and optimisation of out of hospital and
in-hospital logistics to shorten door to balloon delays.20 26–29
The multivariate analysis for predicting in-hospital mor-
tality at admission also confirmed the benefit associated with
primary PCI and thrombolysis, contrasting with the results
from previous studies.10 15 Furthermore, admission year was a
significant predictor, confirming the improvement in survival
over the study period.
Limitations
Although at the time of this study 54 of the 106 hospitals
treating STEMI in Switzerland were participating in the
AMIS Plus registry, the number of the participating centres
varied during the study period and they may therefore not be
entirely representative of all the hospitals in the country.
Thus, the absolute number of patients may not give a true
picture of the national incidence of myocardial infarction
leading to hospital admission. This should improve over the
coming years as more centres join the project.
Another limitation, which is common to all registries, is
that AMIS Plus is an observational study rather than a
randomised trial. Some of the baseline characteristics of the
patients were not available and may thus have created
unrecognised bias. Nevertheless, although the participating
centres were not individually audited on site, the data
management centre continuously and carefully checked the
data questionnaires and queried incomplete questionnaires
as needed.
Lastly, it is important to mention that, although AMIS Plus
is supported by unrestricted grants from several pharmaceu-
tical and medical device companies, the data were collected
and analysed independently. The sponsoring firms had no
access to the raw data.
Conclusions
From 1997 to 2002, the use of reperfusion for STEMI has
increased progressively in Switzerland, with primary PCI
becoming the preferred mode of reperfusion since 2002. This
shows that the information from randomised controlled trials
and guidelines is adequately reshaping daily clinical practice
for the management of STEMI.6–8 Along with this progres-
sion, in-hospital mortality decreased greatly over the same
period. However, about one third of the patients still did not
receive reperfusion therapy in 2002. A continued effort is
therefore necessary to make reperfusion available to a greater
Table 2 Multivariate analysis for predicting in-hospital mortality at admission (n = 4993)
OR 95% CI for OR p Value
Primary PCI 0.52 0.33 to 0.81 0.004
Thrombolysis 0.63 0.47 to 0.83 0.001
Admission year (per additional year)* 0.87 0.81 to 0.94 ,0.001
Age (per additional year) 1.07 1.06 to 1.08 ,0.001
Female sex 1.42 1.11 to 1.82 0.005
Heart rate (per additional beat/min) 1.011 1.006 to 1.015 ,0.001
Systolic BP (per additional mm Hg) 0.98 0.98 to 0.99 ,0.001
Killip class II 1.71 1.29 to 2.27 ,0.001
Killip class III 3.61 2.49 to 5.24 ,0.001
Killip class IV 5.97 3.51 to 10.17 ,0.001
Q wave on ECG 1.43 1.13 to 1.83 ,0.001
Pre-hospital CPR 3.02 1.98 to 4.59 ,0.001
*From 1997 to 2002.
CI, confidence interval; OR, odds ratio.
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proportion of patients with STEMI, in particular to those
admitted late after symptom onset.
Moreover, at a time when modern cardiology is changing
rapidly, with new strategies such as transferring patients for
primary PCI and evaluating facilitated PCI,21 30–33 registries
such as AMIS Plus should help us to assess the applicability
and effectiveness of these potential changes to come and to
contribute to improved care for patients with STEMI.
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Cardiomyopathy induced by performance enhancing drugs in a competitive bodybuilder
A
36 year old competitive body-
builder presented with increasing
dyspnoea on exertion over a six
week period. He gave a 10 year history
of use of anabolic steroids, growth
hormone, ephedrine, and thyroxine.
Echocardiography demonstrated severe
left ventricular hypertrophy and systolic
dysfunction. Serum ferritin was normal
and there was no serological evidence of
viral infection or connective tissue dis-
ease. Angiography revealed normal cor-
onary arteries and cardiac magnetic
resonance imaging (CMR) was per-
formed to further investigate the cause
of the cardiomyopathy. The left ventri-
cle, shown here in end diastole (panel
A) was noted to be severely hypertro-
phied (myocardial mass 465 g; normal
range 85–181 g), dilated (end diastolic
volume 319 ml; normal range 102–
235 ml), and systolic function was
severely impaired (ejection fraction
20%). Imaging post administration of
gadolinium-DTPA was negative for late
enhancement (panel B), excluding both
myocardial infarction and macroscopic
evidence of myocardial fibrosis. Initial
treatment has been commenced with a
diuretic, angiotensin converting enzyme
inhibitor, b blocker, and anticoagula-
tion. Growth hormone excess has been
associated with left ventricular hyper-
trophy while anabolic steroids have
been associated both with myocardial
hypertrophy, focal myocardial fibrosis,
and premature myocardial infarction.
Thyroxine may cause high output
cardiac failure. CMR is the non-invasive
investigation of choice in unexplained
heart failure. This case illustrates that
severe heart failure can occur in patients
taking these performance enhancing
drugs without CMR evidence of either
myocardial infarction or myocardial
fibrosis.
P B Mark
S Watkins
H J Dargie
pm124p@clinmed.gla.ac.uk
Short axis view of the left ventricle in end
diastole showing severe left ventricular
hypertrophy and dilation as well as
demonstrating an incidental pectoral implant,
seen in the upper section of the image.
Horizontal long axis view of the hypertrophied
left ventricle post-gadolinium with the
myocardium nulled, demonstrating no areas of
gadolinium enhancement.
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